Glycorex continues to build and strengthen the company and as part of this, Lars Juliusson has been recruited as Business Development Manager with the aim of leading the company's establishment in the field of transfusion medicine.
Glycorex has recruited Lars Juliusson to lead the work of establishing the company's unique product in the field of transfusion. Lars has more than 30 years of experience in sales of medical devices and has for the past six years worked in transfusion medicine as Country Manager Nordic at MacoPharma. Previously, Lars has held leading positions at the medical device companies EssMed and CellaVision.
"We are delighted to welcome Lars to Glycorex. His long experience in sales to transfusion clinics and blood banks, as well as his drive and motivation will be important assets for Glycorex going forward", said Johan Lavén, CEO of Glycorex.
"I feel honoured and excited about the opportunity to be part of Glycorex's journey to establish its product in transfusion medicine. Access to safe blood products in healthcare is extremely important, not least in emergency situations. Here I believe the company's product can play a crucial role in different organisations and applications. I look forward to all the interesting discussions and to working with the healthcare sector to increase access to universal blood products," said Lars Juliusson.
Lars will start his employment as soon as his current commitments end.
For more information, please contact
Johan Lavén, CEO
Tel: + 46 (0)73 330 92 16
Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Lund, Sweden. The company has developed a unique technology to select and remove specific antibodies in the blood. The company’s focus areas are within transplantation, blood transfusion and blood products as well as autoimmune diseases. The company has sales in over 25 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets. Product development and production takes place in the company’s own facility in Lund, Sweden.
The company's self-developed proprietary medical device, Glycosorb® ABO, has been used worldwide since 2001 to facilitate over 6,000 blood group incompatible transplants by specifically reducing the anti-A/B antibody titers in the transplant recipient’s plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver, heart, lung, and stem cell transplants. More than 60 scientific papers have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO.
The company has also developed a CE-marked medical device for the production of universal (low titer) blood products and is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM (Nordic Growth Market) Main Regulated Equity and is traded under the symbol GTAB B.